Navigation Links
Pregabalin Proves Durable Pain Relief Option for Fibromyalgia

Pregabalin, typically used to treat nerve pain or seizures, appears to offer extended pain relief for those with fibromyalgia, according to research presented this week at// the American College of Rheumatology Annual Scientific Meeting in Washington, DC.

Fibromyalgia is an often misunderstood syndrome that causes widespread chronic muscle pain and tenderness in 2 percent of the U.S. population, most commonly women. In addition to pain, fibromyalgia is often associated with fatigue, sleep disturbances and memory problems. Unfortunately, to date, no FDA-approved treatment has been available for this syndrome.

Researchers enrolled 1,051 participants in a six-week program of 300, 450 or 600 mg daily doses of pregabalin to optimize pain control and medication tolerance. On average, the population was 93% female, 88% white, had endured fibromyalgia for over seven years and measured their pain severity as 78 on a 100 point scale.

At the end of the 6-week program, 663 participants (63%) cited over 50% reduction in pain, and being “much” or “very much improved.” Of these, 566 were randomized into a 26-week double-blind study to receive either pregabalin at the optimal dosage established during the 6 weeks prior or placebo. The primary goal of this six-month study, one of the longest control studies conducted to date, was to determine how long their therapeutic responses lasted.

One-fourth of placebo-treated patients saw worsening by day 7 as compared to day 34 for those on medication. By the end of the double-blind treatment, nearly twice (61%) as many placebo patients had lost response as compared to 32% of the patients on medication. The most common side effects of pregabalin were dizziness, somnolence, sinusitis, joint pain and anxiety. One death occurred each in the placebo and treatment arms of the trial, but neither was treatment-related.

“Fibromyalgia is a common and often debilitating pain syndrome,” expl ains Leslie J. Crofford, MD, Gloria W. Singletary Professor of Rheumatology & Women’s Health, University of Kentucky, Lexington, Kentucky, and an investigator in the study. “The results of this six-month study indicate pregabalin has a significant benefit in terms of longer-term pain relief for these patients.”

Source-Newswis
SRM
'"/>




Related medicine news :

1. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
2. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
3. Pilot Study Proves Home Abortions ‘Safe’
4. Many Nonprescription Cough Medicines Proves Ineffective
5. Less Invasive By Pass Surgery Proves Economical In The Long Run
6. Epidural Mistakes Proves To Be Fatal Blunders
7. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
8. Drug Trial Proves Nightmare for British Indian Student
9. Naturopathic Care Proves Beneficial for TMD Pain
10. Medtronic Device Proves Effective in Parkinson’s Diseas
11. Large Community Spirometry Screening Proves Successful
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology: